<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902264</url>
  </required_header>
  <id_info>
    <org_study_id>16484</org_study_id>
    <nct_id>NCT01902264</nct_id>
  </id_info>
  <brief_title>Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception</brief_title>
  <official_title>Prospective, Open-label, Single-center Clinical Study to Investigate the Red Blood Cell and Plasma Folate Concentrations During a 24-week Treatment Period With the Combination of Drospirenone 3 mg Plus Ethinyl Estradiol 0.02 mg Plus Levomefolate Calcium 0.451 mg in Mexican Women Seeking Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the red blood cell (RBC) and plasma concentrations&#xD;
      of folate in subjects treated with drospirenone (DRSP)/ethinyl estradiol (EE) plus&#xD;
      levomefolate calcium (L-5-MTHF) at 24 weeks with respect to basal determination.&#xD;
&#xD;
      Increased intake of folic acid (synthetic form of the naturally occurring B-vitamin) before&#xD;
      and in the first few weeks of pregnancy has been shown to reduce certain types of birth&#xD;
      defects. This is important for women who may become pregnant following discontinuation of&#xD;
      oral contraception. Information about any side effects that may occur will also be collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in RBC folate concentration from baseline to Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma folate concentration from baseline to Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RBC folate concentration</measure>
    <time_frame>Different time points up to 32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma folate concentration</measure>
    <time_frame>Different time points up to 32 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>EE20/DRSP/L-5-MTHF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)</intervention_name>
    <description>One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks</description>
    <arm_group_label>EE20/DRSP/L-5-MTHF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, Mexican female subjects requesting contraception&#xD;
&#xD;
          -  Age &gt;/=18 to &lt;/=45 years (inclusive); smokers must not be older than 30 years at the&#xD;
             time of informed consent&#xD;
&#xD;
          -  Normal or clinically insignificant cervical smear not requiring further follow-up; a&#xD;
             cervical smear has to be taken at the screening visit, or a normal result has to be&#xD;
             documented within the previous 6 months. Human papilloma virus (HPV) testing in&#xD;
             subjects with atypical squamous cells of undetermined significance (ASCUS) can be used&#xD;
             as an adjunctive test. Subjects with ASCUS can be included if they are negative for&#xD;
             high-risk HPV strains.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation (less than 6 months since delivery, abortion, or lactation&#xD;
             before start of treatment)&#xD;
&#xD;
          -  Body mass index (BMI) &gt;30 kg/m2&#xD;
&#xD;
          -  Hypersensitivity to any ingredient in the study drug&#xD;
&#xD;
          -  Any diseases or conditions that can compromise the function of body systems and could&#xD;
             result in altered absorption, excessive accumulation, impaired metabolism, or altered&#xD;
             excretion of the study medication&#xD;
&#xD;
          -  Any diseases or conditions that might interfere with the conduct of the study or the&#xD;
             interpretation of the results&#xD;
&#xD;
          -  Any disease or condition that may worsen under hormonal treatment according to the&#xD;
             assessment and opinion of the investigator.&#xD;
&#xD;
          -  Undiagnosed abnormal genital bleeding&#xD;
&#xD;
          -  Abuse of alcohol, drugs or medicine (eg, laxatives)&#xD;
&#xD;
          -  Any medication that could result in excessive accumulation, impaired metabolism, or&#xD;
             altered excretion of the study drug&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mexico, D.F.</city>
        <state>Distrito Federal</state>
        <zip>CP 14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>July 15, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Levomefolate calcium</keyword>
  <keyword>Contraceptives, oral, combined</keyword>
  <keyword>Neural tube defects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

